MedTrace Logo

Mesalazine Granules vs. Placebo for the Prevention of Recurrence of Diverticulitis

NCT00695643 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 345

Last updated 2017-07-24

No results posted yet for this study

Summary

The purpose of the study is to determine whether mesalazine granules compared to placebo is effective in prevention of recurrence of disease.

Conditions

  • Diverticulitis

Interventions

DRUG

Mesalazine

3 g per day

DRUG

Placebo

0 g per day

Sponsors & Collaborators

  • Dr. Falk Pharma GmbH

    lead INDUSTRY

Principal Investigators

  • Wolfgang Kruis, Professor · Evang. Krankenhaus Kalk, Medical department

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-01-31
Primary Completion
2011-11-30
Completion
2012-01-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00695643 on ClinicalTrials.gov